Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.
Zinc finger transcription factors, IKZF1 and IKZF3, involved in immune cell development and homeostasis, are overexpressed in the cells of patients with SLE. As such, iberdomide, a
high‐affinity cereblon ligand which promotes proteasomal degradation of IKZF1 and IKZF3, is currently in development for the treatment of patients with SLE, multiple myeloma and lymphoma.
Following a successful Phase 2a study, Lipsky, et al. further evaluate the effects of iberdomide on immunologic biomarkers in patients with active SLE, with promising results for future clinical practice and development.